AstraZeneca PLC (AZN)vsRigel Pharmaceuticals Inc (RIGL)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
RIGL
Rigel Pharmaceuticals Inc
$47.24
-0.08%
HEALTHCARE · Cap: $909.15M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 22071% more annual revenue ($61.37B vs $276.79M). RIGL leads profitability with a 116.3% profit margin vs 17.0%. RIGL trades at a lower P/E of 2.9x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
RIGL
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+86.1%
Fair Value
$251.76
Current Price
$47.24
$204.52 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 76 in profit
Keeps 116 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 29.9%
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Revenue declined 22.6%
Earnings declined 73.2%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 116.3% and operating margin at 29.9%.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while RIGL is a declining play — different risk/reward profiles.
RIGL carries more volatility with a beta of 1.20 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 54/100), backed by strong 17.0% margins. RIGL offers better value entry with a 86.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?